What is HC Wainwright’s Forecast for LXEO FY2024 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($3.22) per share for the year, down from their previous forecast of ($2.75). HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.00) EPS and FY2025 earnings at ($3.84) EPS.

Several other equities research analysts have also recently weighed in on the company. Chardan Capital increased their target price on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Finally, Leerink Partners dropped their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $22.71.

Lexeo Therapeutics Trading Down 14.5 %

Shares of LXEO stock opened at $6.65 on Monday. The stock has a market capitalization of $219.92 million and a PE ratio of -2.10. Lexeo Therapeutics has a 1-year low of $6.65 and a 1-year high of $22.33. The business has a 50-day moving average of $9.01 and a 200 day moving average of $12.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 9.38.

Insider Transactions at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00. Following the completion of the transaction, the chief executive officer now owns 120,695 shares of the company’s stock, valued at $977,629.50. This trade represents a 3.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 12,500 shares of company stock valued at $113,300. Corporate insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LXEO. BNP Paribas Financial Markets increased its holdings in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Lexeo Therapeutics in the 3rd quarter worth $67,000. American International Group Inc. bought a new stake in shares of Lexeo Therapeutics in the 1st quarter worth $79,000. MetLife Investment Management LLC increased its holdings in shares of Lexeo Therapeutics by 121.5% in the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after purchasing an additional 7,803 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Lexeo Therapeutics by 37.3% in the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after purchasing an additional 3,627 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.